Therapeutic Cancer Vaccines: Mechanisms, Clinical Evidence and Translational Challenges

Read full text Summarise with VIRAT
Authors: Rithvik Nasika
Cited by: 0
References: 14

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Cancer has persisted as one of the major causative agents of death around the world, fueled by factors associated with the uncontrolled growth of mutated cells that are normally difficult to recognize by the body’s immune system or to combat using conventional therapeutic approaches that include chemotherapy, irradiation, and surgery. This paper reviews various cancer vaccines, which have emerged as among the most promising immunotherapies. Cancer vaccines induce anticancer responses by activating the body’s adaptive immune system to recognize and destroy cancer cells. Fundamentally, cancer vaccines fall into several categories, including preventive, cell-based, nucleic acid-based, peptide/protein-based, and oncolytic viral vaccines. Currently, several clinical studies indicate that several forms of cancer vaccines offer effective promise in their ability to induce effective T cell responses in cancer patients, although these vaccines remain far from having achieved widespread clinical implementation due to several underlying challenges associated with cancer vaccines, including immunosuppressive tumor microenvironments, antigens’ immunogenicity, and the high production and engineering complexity of personalized vaccines. Nonetheless, cancer vaccines show unequivocal promise as one of the most effective approaches in cancer therapy in the near future.

Fields of Study & Subjects

Immunotherapy and Immune Responses Cancer Immunotherapy and Biomarkers Bacterial Cancer Therapy

Publication details

Journal / source
American journal of student research.
Pages
215–222
Publication date
1 January 2026
Language
EN